title: Prophylactic cranial irradiation for small-cell lung cancer: how, when and for whom?
abstract: Prophylactic cranial irradiation (PCI) reduces the incidence of brain metastases and improves overall survival in both limited disease (LD) and extensive disease (ED) small-cell lung cancer (SCLC), in complete and good responders to initial chemo(radio)therapy. In LD-SCLC, a standard dose of 25 Gy given in ten fractions is recommended, whereas in ED-SCLC a shorter schedule of 20 Gy in five fractions could be used. The issues of acute neurotoxicity (NT) and the potential impact of PCI on quality of life are of particular concern in ED-SCLC patients, as their expected survival is short. In LD-SCLC late neurologic sequelae may worsen quality-adjusted life expectancy for long-term survivors, as the pronounced effect of NT becomes apparent after several years. Some novel potential approaches to reduce the PCI-related late NT have recently been investigated. Despite the growing incidence of lung cancer in elderly people, there are no established standards of treatment for this subset of the population.
authors.affiliation: Regional Oncology Center, Czestochowa, Poland.
authors.forename: Joanna
authors.initials: J
authors.lastname: Socha
authors.forename: Lucyna
authors.initials: L
authors.lastname: Kępka
mesh_terms: D001932:Brain Neoplasms / Q000517:prevention & control / Q000532:radiotherapy* / Q000556:secondary; D018288:Carcinoma, Small Cell / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000532:radiotherapy*; D011788:Quality of Life